at CNBC.com (Sep 26, 2013)
Onyx Pharmaceuticals (ONXX) +3.8% premarket as shares are upgraded to Outperform with a price...
Onyx Pharmaceuticals (ONXX) +3.8% premarket as shares are upgraded to Outperform with a price target of $82 (from $65) at Leerink Swann. The firm says the failure of Bristol-Myers' (BMY -0.4%) brivanib to meet its primary survival objective is a "significant positive" for the long-term outlook for ONXX's Nexavar liver cancer treatment.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Fox Business (Sep 19, 2013)
at CNBC.com (Aug 27, 2013)
at CNBC.com (Aug 26, 2013)
at MarketWatch.com (Aug 26, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs